kabutan

OncoTherapy Science, Inc.(4564) Summary

4564
TSE Growth
OncoTherapy Science, Inc.
24
JPY
0
(0.00%)
Apr 30, 9:01 am JST
0.14
USD
Apr 29, 8:01 pm EDT
Result
PTS
outside of trading hours
23.5
Apr 30, 9:01 am JST
Summary Chart Historical News Financial Result
PER
PBR
4.45
Yield
ー%
Margin Trading Ratio
4.45
Stock Price
Apr 30, 2026
Opening Apr 30, 9:00 am
23 JPY 0.14 USD
Previous Close Apr 28
24 JPY 0.15 USD
High Apr 30, 9:01 am
24 JPY 0.14 USD
Low Apr 30, 9:00 am
23 JPY 0.14 USD
Volume
87,934,600
Trading Value
2.02B JPY 0.01B USD
VWAP
23.0 JPY 0.14 USD
Minimum Trading Value
2,400 JPY 14 USD
Market Cap
9.21B JPY 0.06B USD
Number of Trades
3
Liquidity & Number of Trades
As of Apr 30, 2026
Liquidity
Mid
1-Year Average
262
1-Year High Apr 20, 2026
2,438
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 2,681,100 20,477,300 7.64
Apr 17, 2026 3,038,100 18,437,500 6.07
Apr 10, 2026 1,995,000 16,281,400 8.16
Apr 3, 2026 1,400,500 14,053,000 10.03
Mar 27, 2026 453,500 16,181,600 35.68
Company Profile
OncoTherapy Science, Inc. is a drug discovery venture originating from the Institute of Medical Science at the University of Tokyo. The company's main focus is on cancer gene analysis and the development of cancer therapeutics.
Sector
Pharmaceuticals
OncoTherapy Science, Inc. is a research and development-oriented venture that broadly engages in cancer drug development, from drug discovery research to clinical trials. The company promotes R&D in various areas including small molecule drugs, cancer peptide vaccines, and antibody drugs, with multiple ongoing clinical trials. Through its subsidiary, OncoTherapy Science also conducts large-scale cancer gene analysis tests and research and development of cancer immunotherapy, thus engaging in cancer precision medicine-related businesses. The company aims to realize personalized medicine through these efforts. OncoTherapy Science has established a staged revenue model including upfront payments, milestones, and royalties through partnerships with major pharmaceutical companies. The company is characterized by its long-term approach to research and development. As a result, its financial performance largely depends on the development progress of partnering pharmaceutical companies and the sales status of pharmaceuticals, which may not be reflected in short-term results in many cases.